Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
H N Ginsberg, … , R Norum, W V Brown
H N Ginsberg, … , R Norum, W V Brown
Published November 1, 1986
Citation Information: J Clin Invest. 1986;78(5):1287-1295. https://doi.org/10.1172/JCI112713.
View: Text | PDF
Research Article Article has an altmetric score of 3

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

  • Text
  • PDF
Abstract

Previous data suggest that apolipoprotein (apo) CIII may inhibit both triglyceride hydrolysis by lipoprotein lipase (LPL) and apo E-mediated uptake of triglyceride-rich lipoproteins by the liver. We studied apo B metabolism in very low density (VLDL), intermediate density (IDL), and low density lipoproteins (LDL) in two sisters with apo CIII-apo AI deficiency. The subjects had reduced levels of VLDL triglyceride, normal LDL cholesterol, and near absence of high density lipoprotein (HDL) cholesterol. Compartmental analysis of the kinetics of apo B metabolism after injection of 125I-VLDL and 131I-LDL revealed fractional catabolic rates (FCR) for VLDL apo B that were six to seven times faster than normal. Simultaneous injection of [3H]glycerol demonstrated rapid catabolism of VLDL triglyceride. VLDL apo B was rapidly and efficiently converted to IDL and LDL. The FCR for LDL apo B was normal. In vitro experiments indicated that, although sera from the apo CIII-apo-AI deficient patients were able to normally activate purified LPL, increasing volumes of these sera did not result in the progressive inhibition of LPL activity demonstrable with normal sera. Addition of purified apo CIII to the deficient sera resulted in 20-50% reductions in maximal LPL activity compared with levels of activity attained with the same volumes of the native, deficient sera. These in vitro studies, together with the in vivo results, indicate that in normal subjects apo CIII can inhibit the catabolism of triglyceride-rich lipoproteins by lipoprotein lipase.

Authors

H N Ginsberg, N A Le, I J Goldberg, J C Gibson, A Rubinstein, P Wang-Iverson, R Norum, W V Brown

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 Total
Citations: 2 2 7 13 18 34 13 12 13 15 9 13 7 9 14 6 20 5 3 10 7 13 9 7 10 12 8 7 10 7 12 10 2 4 10 3 4 5 365
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (365)

Title and authors Publication Year
Apolipoprotein B Secretion Assay from Primary Hepatocytes
Wang Y, Li X, Huang R, Chen XW, Wang X
Bio-protocol 2024
Macromolecular Interactions of Lipoprotein Lipase (LPL).
Wheless A, Gunn KH, Neher SB
Sub-cellular biochemistry 2024
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here
Hermel M, Lieberman M, Slipczuk L, Rana JS, Virani SS
Pharmaceutics 2023
Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids.
Naber A, Demus D, Slieker R, Nicolardi S, Beulens JWJ, Elders PJM, Lieverse AG, Sijbrands EJG, 't Hart LM, Wuhrer M, van Hoek M
International journal of molecular sciences 2023
Postprandial metabolism of apolipoproteins B48, B100, C-III and E in in humans heterozygous for APOC3 loss-of-function mutations
Marja-Riitta Taskinen, Elias Björnson, Niina Matikainen, Sanni Söderlund, Joel Rämo, Mari Ainola, Antti Hakkarainen, Carina Sihlbom, Annika Thorsell, Linda Andersson, stefano romeo, Martin Adiels, Samuli Ripatti, Markku Laakso, Chris J Packard, Jan Borén
JCI Insight 2022
RNA-based therapy in the management of lipid disorders: a review.
Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ
Lipids in Health and Disease 2022
Malnourishment affects gene expression along the length of the small intestine
Pinho RM, Garas LC, Huang BC, Weimer BC, Maga EA
Frontiers in Nutrition 2022
Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects
M Rodríguez, P Rehues, V Iranzo, J Mora, C Balsells, M Guardiola, J Ribalta
Journal of Proteomics 2022
Associations between Alcohol Consumption and HDL Subspecies Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study.
Wilkens TL, Sørensen H, Jensen MK, Furtado JD, Dragsted LO, Mukamal KJ
Current Problems in Cardiology 2022
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim JY, Kim NH
Journal of Lipid and Atherosclerosis 2022
Broadening the scope of dyslipidemia therapy by targeting APOC3 and ANGPTL3
Ginsberg HN, Goldberg IJ
Arteriosclerosis, thrombosis, and vascular biology 2022
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
I Valladolid-Acebes, PO Berggren, L Juntti-Berggren
International journal of molecular sciences 2021
Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
BH Keirns, CM Sciarrillo, NA Koemel, SR Emerson
Journal of Nutritional Science 2021
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
HN Ginsberg, CJ Packard, MJ Chapman, J Borén, CA Aguilar-Salinas, M Averna, BA Ference, D Gaudet, RA Hegele, S Kersten, GF Lewis, AH Lichtenstein, P Moulin, BG Nordestgaard, AT Remaley, B Staels, ES Stroes, MR Taskinen, LS Tokgözoğlu, A Tybjaerg-Hansen, JK Stock, AL Catapano
European Heart Journal 2021
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
RA Calle, NB Amin, S Carvajal-Gonzalez, TT Ross, A Bergman, S Aggarwal, C Crowley, A Rinaldi, J Mancuso, N Aggarwal, V Somayaji, M Inglot, TA Tuthill, K Kou, M Boucher, G Tesz, R Dullea, KK Bence, AM Kim, JA Pfefferkorn, WP Esler
Nature Medicine 2021
PCSK9 Activity Is Potentiated Through HDL Binding
SA Burnap, K Sattler, R Pechlaner, E Duregotti, R Lu, K Theofilatos, K Takov, G Heusch, S Tsimikas, C Fernandez-Hernando, SE Berry, WL Hall, M Notdurfter, G Rungger, B Paulweber, J Willeit, S Kiechl, B Levkau, M Mayr
Circulation research 2021
Exploration of Serum Marker Proteins in Mice Induced by Babesia microti Infection Using a Quantitative Proteomic Approach
X Wang, S Ren, X Yang, A Masoudi, X Xue, M Li, H Li, X Zhang, H Wang, J Liu
The Protein Journal 2021
Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets
A von Eckardstein, C Binder
2021
Hypertriglyceridemia Acute Pancreatitis: Animal Experiment Research.
Wang L, Xu T, Wang R, Wang X, Wu D
Digestive Diseases and Sciences 2021
Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia
Y Guan, X Hou, P Tian, L Ren, Y Tang, A Song, J Zhao, L Gao, G Song
Frontiers in Endocrinology 2021
Effects of bariatric surgery on lipid-lipoprotein profile
ME Piché, I Tardif, A Auclair, P Poirier
Metabolism 2021
Working towards full eradication of lipid-driven cardiovascular risk?
NS Nurmohamed, ES Stroes
Netherlands Heart Journal 2021
A lipid lover’s guide to novel therapeutics for lipid and cardiovascular risk reduction
R Hritani, A Hussain, A Saeed, A Agarwala
Future Cardiology 2021
Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism
M Maraninchi, A Calabrese, JP Nogueira, F Castinetti, J Mancini, F Mourre, L Piétri, E Bénamo, F Albarel, I Morange, J Dupont-Roussel, A Nicolay, T Brue, S Béliard, R Valéro
Journal of Clinical Lipidology 2021
Vaccination in Atherosclerosis
FS Nettersheim, LD Vore, H Winkels
Cells 2020
Apolipoprotein CIII and Angiopoietin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin
M Lightbourne, A Wolska, BS Abel, KI Rother, M Walter, Y Kushchayeva, S Auh, RD Shamburek, AT Remaley, R Muniyappa, RJ Brown
Journal of the Endocrine Society 2020
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
NO Stitziel, JE Kanter, KE Bornfeldt
Trends in Molecular Medicine 2020
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
J Borén, CJ Packard, MR Taskinen
Frontiers in Endocrinology 2020
The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
JM Wilson, A Nikooienejad, DA Robins, WC Roell, JS Riesmeyer, A Haupt, KL Duffin, MR Taskinen, G Ruotolo
Diabetes, obesity & metabolism 2020
Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
H Yan, M Niimi, F Matsuhisa, H Zhou, S Kitajima, Y Chen, C Wang, X Yang, J Yao, D Yang, J Zhang, M Murakami, K Nakajima, Y Wang, E Liu, J Liang, YE Chen, J Fan
Arteriosclerosis, thrombosis, and vascular biology 2020
Association of apolipoprotein C3 with insulin resistance and coronary artery calcium in patients with type 1 diabetes
T Buckner, B Shao, RH Eckel, JW Heinecke, KE Bornfeldt, J Snell-Bergeon
Journal of Clinical Lipidology 2020
Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
NS Nurmohamed, GM Thie, ES Stroes
Expert Review of Cardiovascular Therapy 2020
iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.
Chen H, Wu M, Jiang W, Liu X, Zhang J, Yu C
International journal of molecular medicine 2020
Apolipoprotein B48 metabolism in chylomicrons and very low‐density lipoproteins and its role in triglyceride transport in normo‐ and hypertriglyceridemic human subjects
E Björnson, CJ Packard, M Adiels, L Andersson, N Matikainen, S Söderlund, J Kahri, A Hakkarainen, N Lundbom, J Lundbom, C Sihlbom, A Thorsell, H Zhou, MR Taskinen, J Borén
Journal of Internal Medicine 2020
Causes and Consequences of Hypertriglyceridemia
CJ Packard, J Boren, MR Taskinen
Frontiers in Endocrinology 2020
Reduced Reverse Cholesterol Transport Efficacy in Healthy Men with Undesirable Postprandial Triglyceride Response
A Motte, J Gall, JE Salem, E Dasque, M Lebot, E Frisdal, S Galier, EF Villard, E Bouaziz-Amar, JM Lacorte, B Charbit, WL Goff, P Lesnik, M Guerin
Biomolecules 2020
Integrin β3 Deficiency Results in Hypertriglyceridemia Via Disrupting LPL (Lipoprotein Lipase) Secretion
B Xiao, J Mao, B Sun, W Zhang, Y Wang, P Wang, Z Ruan, , H Li, J Zhou, Y Lu, Q Ding, X Wang, J Liu, J Yan, C Luo, X Shi, R Yang,
Arteriosclerosis, thrombosis, and vascular biology 2020
Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective
X Jia, J Liu, A Mehta, CM Ballantyne, SS Virani
Cardiovascular Drugs and Therapy 2020
Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
JL Katzmann, CM Werner, T Stojakovic, W März, H Scharnagl, U Laufs
Lipids in Health and Disease 2020
Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study
M Kaltoft, A Langsted, BG Nordestgaard
European Heart Journal 2020
Oligonucléotide antisens de l’apolipoprotéine C-III : nouveau traitement de certaines hypertriglycéridémies sévères
R Valéro
Médecine des Maladies Métaboliques 2020
Dyslipidemia is the hallmark of the metabolic syndrome in postmenopausal women
AA Osman, AM Fadlalla
2020
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
Henry Ginsberg, Gissette Reyes-Soffer
Journal of Clinical Investigation 2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Renal Fibrosis: Mechanisms and Therapies
BC Liu, HY Lan, LL Lv
2019
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
G Reyes-Soffer, C Sztalryd, RB Horenstein, S Holleran, A Matveyenko, T Thomas, R Nandakumar, C Ngai, W Karmally, HN Ginsberg, R Ramakrishnan, TI Pollin
Arteriosclerosis, thrombosis, and vascular biology 2019
ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
B Ramms, S Patel, C Nora, AR Pessentheiner, MW Chang, CR Green, GJ Golden, P Secrest, RM Krauss, CM Metallo, C Benner, VJ Alexander, JL Witztum, S Tsimikas, JD Esko, PL Gordts
Journal of lipid research 2019
ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors
NC Kegulian, B Ramms, S Horton, O Trenchevska, D Nedelkov, MJ Graham, RG Lee, JD Esko, HN Yassine, PL Gordts
Arteriosclerosis, thrombosis, and vascular biology 2019
Life is complicated: so is apoCIII
G Reyes-Soffer, HN Ginsberg
Journal of lipid research 2019
Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia
M Adiels, MR Taskinen, E Björnson, L Andersson, N Matikainen, S Söderlund, J Kahri, A Hakkarainen, N Lundbom, C Sihlbom, A Thorsell, H Zhou, KH Pietiläinen, C Packard, J Borén
Diabetes, obesity & metabolism 2019
The Future of Lipid-lowering Therapy
Zwol, Rimbert, Kuivenhoven
Journal of Clinical Medicine 2019
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
TD Filippatos, A Liontos, EC Christopoulou, MS Elisaf
Current vascular pharmacology 2019
Apolipoprotein CIII and diabetes. Is there a link?
E Christopoulou, V Tsimihodimos, T Filippatos, M Elisaf
Diabetes/Metabolism Research and Reviews 2019
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
Yamashita, Arai, Yokote, Araki, Matsushita, Nojima, Suganami, Ishibashi
International journal of molecular sciences 2019
The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
PL Gordts, JD Esko
Matrix biology : journal of the International Society for Matrix Biology 2018
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
D Masuda, T Kobayashi, M Sairyou, H Hanada, T Ohama, M Koseki, M Nishida, N Maeda, S Kihara, T Minami, K Yanagi, Y Sakata, S Yamashita
Journal of Atherosclerosis and Thrombosis 2018
An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans
A Mardinoglu, H Wu, E Bjornson, C Zhang, A Hakkarainen, SM Räsänen, S Lee, RM Mancina, M Bergentall, KH Pietiläinen, S Söderlund, N Matikainen, M Ståhlman, PO Bergh, M Adiels, BD Piening, M Granér, N Lundbom, KJ Williams, S Romeo, J Nielsen, M Snyder, M Uhlén, G Bergström, R Perkins, HU Marschall, F Bäckhed, MR Taskinen, J Borén
Cell Metabolism 2018
γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor
KJ Kim, IJ Goldberg, MJ Graham, M Sundaram, E Bertaggia, SX Lee, L Qiang, RA Haeusler, D Metzger, P Chambon, Z Yao, HN Ginsberg, UB Pajvani
Cell Metabolism 2018
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein MetabolismHighlights
DC Chan, GF Watts, R Somaratne, SM Wasserman, R Scott, PH Barrett
Arteriosclerosis, thrombosis, and vascular biology 2018
Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice
H Yingchun, M Yahong, W Jiangping, H Xiaokui, Z Xiaohong
Lipids in Health and Disease 2018
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
JC van Capelleveen, SR Lee, R Verbeek, JJ Kastelein, NJ Wareham, ES Stroes, GK Hovingh, KT Khaw, SM Boekholdt, JL Witztum, S Tsimikas
Journal of Clinical Lipidology 2018
Update on the laboratory investigation of dyslipidemias
I Ramasamy
Clinica chimica acta; international journal of clinical chemistry 2018
Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D
A Basu, AJ Jenkins, JA Stoner, Y Zhang, RL Klein, MF Lopes-Virella, WT Garvey, DS Schade, J Wood, P Alaupovic, TJ Lyons
Journal of lipid research 2018
Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management
WV Brown, I Goldberg, B Duell, D Gaudet
Journal of Clinical Lipidology 2018
Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities
KE Kypreos, R Bitzur, EA Karavia, E Xepapadaki, G Panayiotakopoulos, C Constantinou
Angiology 2018
Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
JC van Capelleveen, SR Lee, R Verbeek, JJ Kastelein, NJ Wareham, ES Stroes, GK Hovingh, KT Khaw, SM Boekholdt, JL Witztum, S Tsimikas
Journal of Clinical Lipidology 2018
Lipid management in patients with chronic kidney disease
CJ Ferro, PB Mark, M Kanbay, P Sarafidis, GH Heine, P Rossignol, ZA Massy, F Mallamaci, JM Valdivielso, J Malyszko, MC Verhaar, R Ekart, R Vanholder, G London, A Ortiz, C Zoccali
Nature Reviews Nephrology 2018
A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening
SJ Lee, M Mahankali, A Bitar, H Zou, E Chao, H Nguyen, J Gonzalez, D Caballero, M Hull, D Wang, PG Schultz, W Shen
Scientific Reports 2017
Apolipoprotein C-III Levels and Incident Coronary Artery Disease RiskHighlights: The EPIC-Norfolk Prospective Population Study
JC van Capelleveen, SJ Moens, X Yang, JJ Kastelein, NJ Wareham, AH Zwinderman, ES Stroes, JL Witztum, GK Hovingh, KT Khaw, SM Boekholdt, S Tsimikas
Arteriosclerosis, thrombosis, and vascular biology 2017
Bile Acids in Gastroenterology
S Tazuma, H Takikawa
Bile Acids in Gastroenterology 2017
Lipid deposition in kidney diseases: interplay among redox, lipid mediators and renal impairment
H Su, C Wan, CT Lei, CY Zhang, C Ye, H Tang, Y Qiu, C Zhang
Antioxidants & Redox Signaling 2017
The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation
M Sundaram, KR Curtis, MA Alipour, ND LeBlond, KD Margison, RA Yaworski, RJ Parks, AD McIntyre, RA Hegele, MD Fullerton, Z Yao
Journal of lipid research 2017
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
NL Meyers, M Larsson, E Vorrsjö, G Olivecrona, DM Small
Journal of lipid research 2017
Lycopene amends LPS induced oxidative stress and hypertriglyceridemia via modulating PCSK-9 expression and Apo-CIII mediated lipoprotein lipase activity
SS Alvi, IA Ansari, MK Ahmad, J Iqbal, MS Khan
Biomedicine & Pharmacotherapy 2017
Genome-Wide Association Study Reveals Four Loci for Lipid Ratios in the Korean Population and the Constitutional Subgroup
T Kim, AY Park, Y Baek, S Cha, BO Tayo
PloS one 2017
Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
SD Prato, R Chilton
Diabetes, obesity & metabolism 2017
P-407-induced Mouse Model of Dose-controlled Hyperlipidemia and Atherosclerosis: 25 Years Later
TP Johnston, TA Korolenko, A Sahebkar
Journal of Cardiovascular Pharmacology 2017
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
S Ishibashi, H Arai, K Yokote, E Araki, H Suganami, S Yamashita
Journal of Clinical Lipidology 2017
Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects
M Maraninchi, N Padilla, S Béliard, B Berthet, JP Nogueira, J Dupont-Roussel, J Mancini, AB Corroller, N Dubois, R Grangeot, C Mattei, M Monclar, A Calabrese, C Guérin, C Desmarchelier, A Nicolay, C Xiao, P Borel, GF Lewis, R Valéro
Journal of Clinical Lipidology 2017
ApoC-III Modulates Clearance of Triglyceride-Rich Lipoproteins Through LDL Family Receptors
Philip L.S.M. Gordts, Ryan Nock, Ni-Huiping Son, Bastian Ramms, Irene Lew, Jon Gonzales, Bryan Thacker, Debapriya Basu, Richard Lee, Adam Mullick, Mark Graham, Ira J. Goldberg, rosanne Crooke, Joseph Witztum, Jeffrey D. Esko
Journal of Clinical Investigation 2016
The role of bile acids in metabolic regulation
L Vítek, M Haluzík
Journal of Endocrinology 2016
Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis
S Morita
Biological & Pharmaceutical Bulletin 2016
Loganin inhibits the inflammatory response in mouse 3T3L1 adipocytes and mouse model
Y Li, Z Li, L Shi, C Zhao, B Shen, Y Tian, H Feng
International Immunopharmacology 2016
The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation
MB Mobin, S Gerstberger, D Teupser, B Campana, K Charisse, MH Heim, M Manoharan, T Tuschl, M Stoffel
Nature Communications 2016
Impaired postprandial lipemic response in chronic kidney disease
JM Saland, LM Satlin, J Zalsos-Johnson, S Cremers, HN Ginsberg
Kidney International 2016
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease
QM Anstee, D Seth, CP Day
Gastroenterology 2016
Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III
EM Ooi, DC Chan, L Hodson, M Adiels, J Boren, F Karpe, BA Fielding, GF Watts, PH Barrett
European Journal of Clinical Investigation 2016
Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
GM Dallinga-Thie, J Kroon, J Borén, MJ Chapman
Current Cardiology Reports 2016
Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase–Independent EffectsCLINICAL PERSPECTIVE
F Drenos, GD Smith, M Ala-Korpela, J Kettunen, P Würtz, P Soininen, AJ Kangas, C Dale, DA Lawlor, TR Gaunt, JP Casas, NJ Timpson
Circulation. Cardiovascular genetics 2016
Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3′UTR variant SstI
M Dancer, C Caussy, MD Filippo, P Moulin, C Marçais, S Charrière
Atherosclerosis 2016
Population Semiphysiologic Kinetic Modeling and Simulation of Plasma Triglyceride Levels After Soybean Oil–Based Intravenous Lipid Emulsion Administration in Rats
A Okada, M Hirano, M Tanioka, T Tsujimoto, H Koyama, A Nishimura, N Shibata, K Fukushima, N Sugioka
JPEN. Journal of parenteral and enteral nutrition 2016
The effect of omega-3 carboxylic acids on apolipoprotein CIII−containing lipoproteins in severe hypertriglyceridemia
AM Morton, JD Furtado, J Lee, W Amerine, MH Davidson, FM Sacks
Journal of Clinical Lipidology 2016
Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes
K Åvall, Y Ali, IB Leibiger, B Leibiger, T Moede, M Paschen, A Dicker, E Daré, M Köhler, E Ilegems, MH Abdulreda, M Graham, RM Crooke, VS Tay, E Refai, SK Nilsson, S Jacob, L Selander, PO Berggren, L Juntti-Berggren
Proceedings of the National Academy of Sciences 2015
Update on the molecular biology of dyslipidemias
I Ramasamy
Clinica Chimica Acta 2015
Genetic background in nonalcoholic fatty liver disease: A comprehensive review
FS Macaluso
World journal of gastroenterology : WJG 2015
Apolipoprotein C-III: From Pathophysiology to Pharmacology
GD Norata, S Tsimikas, A Pirillo, AL Catapano
Trends in Pharmacological Sciences 2015
Hypertriglyceridemia in the Genomic Era: A New Paradigm
GF Lewis, C Xiao, RA Hegele
Endocrine reviews 2015
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone
GE Ronsein, G Reyes-Soffer, Y He, M Oda, H Ginsberg, JW Heinecke
Molecular & cellular proteomics : MCP 2015
Cholesterol Metabolism in CKD
AB Reiss, I Voloshyna, JD Leon, N Miyawaki, J Mattana
American Journal of Kidney Diseases 2015
The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia:
FM Sacks
Current Opinion in Lipidology 2015
Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination
SB Patel
Metabolic Syndrome and Related Disorders 2015
Saroglitazar, a novel PPAR α / γ agonist with predominant PPAR α activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
MR Jain, SR Giri, C Trivedi, B Bhoi, A Rath, G Vanage, P Vyas, R Ranvir, PR Patel
Pharmacology Research & Perspectives 2015
Tryptophan probes reveal residue-specific phospholipid interactions of apolipoprotein C-III
CM Pfefferkorn, RL Walker, Y He, JM Gruschus, JC Lee
Biochimica et Biophysica Acta (BBA) - Biomembranes 2015
Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
RL Dunbar, SJ Nicholls, KC Maki, EM Roth, DG Orloff, D Curcio, J Johnson, D Kling, MH Davidson
Lipids in Health and Disease 2015
JCL roundtable: Apolipoproteins as causative elements in vascular disease
WV Brown, FM Sacks, AD Sniderman
Journal of Clinical Lipidology 2015
The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
MC von Ballmoos, B Haring, FM Sacks
Journal of Clinical Lipidology 2015
Genetic variation in insulin-induced kinase signaling
IX Wang, G Ramrattan, VG Cheung
Molecular Systems Biology 2015
Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels
G Ehx, S Gérin, G Mathy, F Franck, HC Oliveira, AE Vercesi, FE Sluse
Lipids in Health and Disease 2014
Tissue-specific DNA methylation profiles regulate liver-specific expression of the APOA1/C3/A4/A5 cluster and can be manipulated with demethylating agents on intestinal cells
M Guardiola, I Oliva, A Guillaumet, Á Martín-Trujillo, R Rosales, JC Vallvé, F Sabench, D Castillo, S Zaina, D Monk, J Ribalta
Atherosclerosis 2014
Comprehensive Physiology
SN Cheuvront, RW Kenefick
Comprehensive Physiology 2014
Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes
ZJ Hu, LP Ren, C Wang, B Liu, GY Song
Experimental and therapeutic medicine 2014
Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
RS Rosenson, MH Davidson, BJ Hirsh, S Kathiresan, D Gaudet
Journal of the American College of Cardiology 2014
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
AB Jørgensen, R Frikke-Schmidt, BG Nordestgaard, A Tybjærg-Hansen
New England Journal of Medicine 2014
Phenotypes and genotypes of high density lipoprotein cholesterol in exceptional longevity
Sofiya Milman, Gil Atzmon, Jill Crandall, Nir Barzilai
Current vascular pharmacology 2014
Diabetes and Kidney Disease
EV Lerma, V Batuman
2014
Cardiac Energy Metabolism in Health and Disease
GD Lopaschuk, NS Dhalla
2014
The genetics of NAFLD
QM Anstee, CP Day
Nature Reviews Gastroenterology & Hepatology 2013
Developments in understanding bile acid metabolism
K Morimoto, H Itoh, M Watanabe
Expert Review of Endocrinology & Metabolism 2013
Relative Quantitation of Glycoisoforms of Intact Apolipoprotein C3 in Human Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry
W Jian, RW Edom, D Wang, N Weng, SW Zhang
Analytical Chemistry 2013
Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association
HE Bays, PP Toth, PM Kris-Etherton, N Abate, LJ Aronne, WV Brown, JM Gonzalez-Campoy, SR Jones, R Kumar, RL Forge, VT Samuel
Journal of Clinical Lipidology 2013
Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families: Two novel mutations in apolipoprotein C3
AE Bochem, JC Capelleveen, GM Dallinga-Thie, AW Schimmel, MM Motazacker, I Tietjen, RR Singaraja, MR Hayden, JJ Kastelein, ES Stroes, GK Hovingh
Clinical Genetics 2013
Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases
D Yang, J Zhang, J Xu, T Zhu, Y Fan, J Fan, YE Chen
Journal of visualized experiments : JoVE 2013
Association between the plasma proteome and plasma α-tocopherol concentrations in humans
LA da Costa, B García-Bailo, CH Borchers, A Badawi, A El-Sohemy
The Journal of Nutritional Biochemistry 2013
Apolipoprotein-defined and NMR lipoprotein subclasses in the Veterans Affairs Diabetes Trial
M Azar, TJ Lyons, P Alaupovic, JA Stoner, C Quiroga, DG Kaufman, M Lopes-Virella, RL Klein, AJ Jenkins
Journal of Diabetes and its Complications 2013
Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment
P Dongiovanni, QM Anstee, L Valenti
Current pharmaceutical design 2013
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
D Yang, J Zhang, J Xu, T Zhu, Y Fan, J Fan, YE Chen
Journal of visualized experiments : JoVE 2013
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
P Dongiovanni, QM Anstee, L Valenti
Current pharmaceutical design 2013
Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
G Reyes-Soffer, CI Ngai, L Lovato, W Karmally, R Ramakrishnan, S Holleran, HN Ginsberg
Diabetes care 2013
Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele
O Olivieri, N Martinelli, M Baroni, A Branchini, D Girelli, S Friso, F Pizzolo, F Bernardi
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2013
Omega-3 fatty acid supplementation and cardiovascular disease: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases
DB Jump, CM Depner, S Tripathy
Journal of lipid research 2012
Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury
S Li, K Nagothu, G Ranganathan, SM Ali, B Shank, N Gokden, S Ayyadevara, J Megyesi, G Olivecrona, SS Chugh, S Kersten, D Portilla
American journal of physiology. Renal physiology 2012
Lipoprotein metabolism in nonalcoholic fatty liver disease
ZG Jiang, SC Robson, Z Yao
Journal of Biomedical Research 2012
New wrinkles in lipoprotein lipase biology
BS Davies, AP Beigneux, LG Fong, SG Young
Current Opinion in Lipidology 2012
Methods in Enzymology
JD Stone, AS Chervin, DH Aggen, DM Kranz
Protein Engineering for Therapeutics Part B 2012
Clinical use of genetic typing in human lipid disorders
WV Brown, J Breslow, C Ballantyne
Journal of Clinical Lipidology 2012
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial
G Reyes-Soffer, CI Ngai, L Lovato, W Karmally, R Ramakrishnan, S Holleran, HN Ginsberg
Diabetes care 2012
Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins
W Qin, M Sundaram, Y Wang, H Zhou, S Zhong, CC Chang, S Manhas, EF Yao, RJ Parks, PJ McFie, SJ Stone, ZG Jiang, C Wang, D Figeys, W Jia, Z Yao
The Journal of biological chemistry 2011
The Metabolic Syndrome
S Devaraj, D Siegel, I Jialal
The Metabolic Syndrome 2011
Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans
F Sentinelli, S Romeo, C Maglio, M Incani, MA Burza, F Scano, F Coccia, E Cossu, F Leonetti, MG Baroni
Lipids in Health and Disease 2011
Effects of Prescription Omega-3-Acid Ethyl Esters on Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia
KC Maki, AL Lawless, KM Kelley, MR Dicklin, VN Kaden, AL Schild, TM Rains, JW Marshall
Journal of Cardiovascular Pharmacology 2011
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
S Ansar, J Koska, PD Reaven
Cardiovascular Diabetology 2011
Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism
G Aragonès, C Alonso-Villaverde, P Pardo-Reche, A Rull, R Beltrán-Debón, E Rodríguez-Gallego, L Fernández-Sender, J Camps, J Joven
BMC Medical Genetics 2011
Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia
KC Maki, HE Bays, MR Dicklin, SL Johnson, M Shabbout
Journal of Clinical Lipidology 2011
Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins: EVIDENCE THAT ApoC-III PLAYS A MAJOR ROLE IN THE FORMATION OF LIPID PRECURSORS WITHIN THE MICROSOMAL LUMEN
W Qin, M Sundaram, Y Wang, H Zhou, S Zhong, CC Chang, S Manhas, EF Yao, RJ Parks, PJ McFie, SJ Stone, ZG Jiang, C Wang, D Figeys, W Jia, Z Yao
The Journal of biological chemistry 2011
GPIHBP1 , an endothelial cell transporter for lipoprotein lipase
SG Young, BS Davies, CV Voss, P Gin, MM Weinstein, P Tontonoz, K Reue, A Bensadoun, LG Fong, AP Beigneux
Journal of lipid research 2011
Apolipoprotein CIII Induces Monocyte Chemoattractant Protein-1 and Interleukin 6 Expression Via Toll-Like Receptor 2 Pathway in Mouse Adipocytes: Retracted
Y Abe, A Kawakami, M Osaka, S Uematsu, S Akira, K Shimokado, FM Sacks, M Yoshida
Arteriosclerosis, thrombosis, and vascular biology 2010
The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients
ES Nakou, TD Filippatos, AP Agouridis, C Kostara, ET Bairaktari, MS Elisaf
Lipids 2010
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia
M Sundaram, S Zhong, MB Khalil, H Zhou, ZG Jiang, Y Zhao, J Iqbal, MM Hussain, D Figeys, Y Wang, Z Yao
Journal of lipid research 2010
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
M Sundaram, S Zhong, MB Khalil, PH Links, Y Zhao, J Iqbal, MM Hussain, RJ Parks, Y Wang, Z Yao
Journal of lipid research 2010
Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII
Y Ding, Y Wang, H Zhu, J Fan, L Yu, G Liu, E Liu
Transgenic Research 2010
Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation
O Olivieri, N Martinelli, D Girelli, F Pizzolo, S Friso, F Beltrame, V Lotto, L Annarumma, R Corrocher
Journal of Thrombosis and Haemostasis 2010
Apolipoprotein CIII bound to apoB-containing lipoproteins is associated with small, dense LDL independent of plasma triglyceride levels in healthy men
MJ Shin, RM Krauss
Atherosclerosis 2010
Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy
KC Maki, MR Dicklin, MH Davidson, RT Doyle, CM Ballantyne
The American Journal of Cardiology 2010
The Effect of APOC3 Promoter Polymorphisms on the Risk of Hypertriglyceridemia in Chinese Han Population With or Without Type 2 Diabetes Mellitus
J Yu, H Wang, S Yang, J Yuan, L Chen, CL Chen, DF Huang, Y Wang, SQ Ju, J Zhu
Laboratory Medicine 2010
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia
M Sundaram, S Zhong, MB Khalil, H Zhou, ZG Jiang, Y Zhao, J Iqbal, MM Hussain, D Figeys, Y Wang, Z Yao
Journal of lipid research 2010
Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins
CO Mendivil, C Zheng, J Furtado, J Lel, FM Sacks
Arteriosclerosis, thrombosis, and vascular biology 2010
Atlas of Atherosclerosis and Metabolic Syndrome
SM Grundy
2010
High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease
EJ Schaefer
2010
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.
Sundaram M, Zhong S, Bou Khalil M, Links PH, Zhao Y, Iqbal J, Hussain MM, Parks RJ, Wang Y, Yao Z
Journal of lipid research 2010
Isoflavones are safe compounds for therapeutical applications – Evaluation of in vitro data
E Reiter, E Reiter, V Beck, S Medjakovic, A Jungbauer
Gynecological Endocrinology 2009
Apolipoprotein CIII Links Dyslipidemia with Atherosclerosis
A Kawakami, M Yoshida
Journal of Atherosclerosis and Thrombosis 2009
Synthesis of reconstituted high density lipoprotein (rHDL) containing apoA-I and apoC-III: the functional role of apoC-III in rHDL
KH Cho
Molecules and Cells 2009
Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk
JW Su, MM Nzekwu, MC Cabezas, T Redgrave, SD Proctor
European Journal of Clinical Investigation 2009
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
M Sundaram, S Zhong, MB Khalil, PH Links, Y Zhao, J Iqbal, MM Hussain, RJ Parks, Y Wang, Z Yao
Journal of lipid research 2009
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III
DT Chan, GK Dogra, AB Irish, EM Ooi, PH Barrett, DC Chan, GF Watts
Journal of lipid research 2009
Endocrine and paracrine role of bile acids
V Keitel, R Kubitz, D Häussinger
World journal of gastroenterology : WJG 2008
Triglyceride-Rich Lipoprotein-Associated Apolipoprotein C-III Production Is Stimulated by Plasma Free Fatty Acids in Humans
M Pavlic, R Valéro, H Duez, C Xiao, L Szeto, BW Patterson, GF Lewis
Arteriosclerosis, thrombosis, and vascular biology 2008
Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses
S Jayanthi, S Buie, S Moore, RI Herning, W Better, NM Wilson, C Contoreggi, JL Cadet
Molecular Psychiatry 2008
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
MA Deeg, MH Tan
PPAR Research 2008
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency
G Gerritsen, CC van der Hoogt, FG Schaap, PJ Voshol, KE Kypreos, N Maeda, AK Groen, LM Havekes, PC Rensen, KW van Dijk
Journal of lipid research 2008
Nitric oxide-releasing agent, LA419, reduces atherogenesis in apolipoprotein E-deficient mice
R Carnicer, N Guillén, JM Arbonés-Mainar, MA Navarro, MA Guzmán, C Barranquero, C Arnal, S Gascón, S Acín, M Mourelle, J Osada
Naunyn-Schmiedeberg's Archives of Pharmacology 2008
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
TI Pollin, CM Damcott, H Shen, SH Ott, J Shelton, RB Horenstein, W Post, JC McLenithan, LF Bielak, PA Peyser, BD Mitchell, M Miller, JR O'Connell, AR Shuldiner
Science 2008
An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
DC Chan, MM Chen, EM Ooi, GF Watts
International Journal of Clinical Practice 2008
Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias
L Duvillard, MJ Caslake, JM Petit, B Vergès, P Gambert, CJ Packard
Atherosclerosis 2008
Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome
EM Ooi, PH Barrett, DC Chan, PJ Nestel, GF Watts
Atherosclerosis 2008
Hyperlipidemia and cardiovascular disease: cardiovascular update
NA Le
Current Opinion in Lipidology 2008
Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein–deficiency states
RD Santos, BF Asztalos, LR Martinez, MH Miname, E Polisecki, EJ Schaefer
Journal of Clinical Lipidology 2008
Alteraciones del metabolismo de las lipoproteínas. Mecanismos etiopatogénicos. Consecuencias fisiopatológicas
CR García-Andrade, LA Walther, JM Núñez-Cortés
Medicine - Programa de Formación Médica Continuada Acreditado 2008
ApoE epsilon2/epsilon3/epsilon4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome
O Olivieri, N Martinelli, A Bassi, E Trabetti, D Girelli, F Pizzolo, S Friso, PF Pignatti, R Corrocher
Clinical and Experimental Medicine 2008
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency
G Gerritsen, CC van der Hoogt, FG Schaap, PJ Voshol, KE Kypreos, N Maeda, AK Groen, LM Havekes, PC Rensen, KW van Dijk
Journal of lipid research 2008
Endocrine and paracrine role of bile acids
V Keitel, R Kubitz, D Häussinger
World journal of gastroenterology : WJG 2008
Apolipoprotein CIII polymorphism and triglyceride levels of a Japanese population living in Southern Brazil
L Parzianello, G Oliveira, JC Coelho
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 2008
Therapeutic Lipidology
MH Davidson, PP Toth, KC Maki, AM Gotto
2008
ABCA1 Promotes the de Novo Biogenesis of Apolipoprotein CIII-Containing HDL Particles in Vivo and Modulates the Severity of Apolipoprotein CIII-Induced Hypertriglyceridemia
KE Kypreos
Biochemistry 2008
Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study
PG Scheffer, T Teerlink, JM Dekker, G Bos, G Nijpels, M Diamant, PJ Kostense, CD Stehouwer, RJ Heine
Clinical chemistry 2008
Lipoprotein metabolism in chronic renal insufficiency
JM Saland, HN Ginsberg
Pediatric Nephrology 2007
High-density lipoprotein and transport of cholesterol and triglyceride in blood
WV Brown
Journal of Clinical Lipidology 2007
The role of hypertriglyceridemia in atherosclerosis
NA Le, MF Walter
Current Atherosclerosis Reports 2007
Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes
L Qi, S Liu, N Rifai, D Hunter, FB Hu
Atherosclerosis 2007
Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency
RD Santos, EJ Schaefer, BF Asztalos, E Polisecki, J Wang, RA Hegele, LR Martinez, MH Miname, CE Rochitte, PL da Luz, RC Maranhão
Journal of lipid research 2007
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
NY Kalaany, DJ Mangelsdorf
Annual Review of Physiology 2006
Visceral Adiposity and Apolipoprotein C-III in Apolipoprotein B-Containing Lipoproteins Are Independent Predictors in Determining Atherogenic Lipid Profiles
T Han, SK Woo, S Shin, HS Kang
Annals of Nutrition and Metabolism 2006
Is apolipoprotein A5 a novel regulator of triglyceride‐rich lipoproteins?
H Jakel, M Nowak, A HelleboidChapman, J FruchartNajib, JC Fruchart
Annals of Medicine 2006
Effects of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Pioglitazone, on Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus
Kazunori Nagashima, Carlos Lopez, Daniel Donovan, Colleen Ngai, Nelson Fontanez, Andre' Bensadoun, Jamila Fruchart-Najib, Steve Holleran, Jeffrey S. Cohen, Rajasekhar Ramakrishnan, Henry N. Ginsberg
Journal of Clinical Investigation 2005
Pathophysiology of dyslipidaemia in the metabolic syndrome
GD Kolovou, KK Anagnostopoulou, DV Cokkinos
Postgraduate medical journal 2005
Antisense oligonucleotides as therapeutics for hyperlipidaemias
RM Crooke
Expert Opinion on Biological Therapy 2005
Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins
D Rimland, JL Guest, I Hernandez, C Rio, NA Le, WV Brown
HIV Medicine 2005
Variations in plasma apolipoprotein C-III levels are strong correlates of the triglyceride response to a high-monounsaturated fatty acid diet and a high-carbohydrate diet
WR Archer, S Desroches, B Lamarche, O Dériaz, N Landry, B Fontaine-Bisson, J Bergeron, P Couture, N Bergeron
Metabolism 2005
Comparison of the Relation of Triglyceride-Rich Lipoproteins and Muscular Artery Compliance in Healthy Women Versus Healthy Men
NA Le, WV Brown, WW Davis, DM Herrington, L Mosca, S Homma, B Eggleston, HJ Willens, JK Raines
The American Journal of Cardiology 2005
ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression
G Gerritsen, PC Rensen, KE Kypreos, VI Zannis, LM Havekes, KW van Dijk
Journal of lipid research 2005
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia
M Myerson, C Ngai, J Jones, S Holleran, R Ramakrishnan, L Berglund, HN Ginsberg
Journal of lipid research 2005
Principles of Molecular Cardiology
MS Runge, C Patterson
2005
Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and “Insulin-Resistant” T−455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction
O Olivieri, N Martinelli, M Sandri, A Bassi, P Guarini, E Trabetti, F Pizzolo, D Girelli, S Friso, PF Pignatti, R Corrocher
Clinical chemistry 2005
Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats
JM Bas, J Fernández-Larrea, M Blay, A Ardèvol, MJ Salvadó, L Arola, C Bladé
The FASEB Journal 2004
Pharmacotherapy of Obesity
FX Pi–Sunyer
Pharmacotherapy of Obesity 2004
The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?
KW van Dijk, PC Rensen, PJ Voshol, LM Havekes
Current Opinion in Lipidology 2004
Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes
L Juntti-Berggren, E Refai, I Appelskog, M Andersson, G Imreh, N Dekki, S Uhles, L Yu, WJ Griffiths, S Zaitsev, I Leibiger, SN Yang, G Olivecrona, H Jörnvall, PO Berggren
Proceedings of the National Academy of Sciences 2004
Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice
K Conde-Knape, K Okada, R Ramakrishnan, NS Shachter
Journal of lipid research 2004
Apolipoprotein C-III SstI Genotypes Modulate Exercise-Induced Hypotriglyceridemia:
SK Woo, HS Kang
Medicine and Science in Sports and Exercise 2004
Effect of the Combination of Methyltestosterone and Esterified Estrogens Compared with Esterified Estrogens Alone on Apolipoprotein CIII and Other Apolipoproteins in Very Low Density, Low Density, and High Density Lipoproteins in Surgically Postmenopausal Women
SE Chiuve, LA Martin, H Campos, FM Sacks
The Journal of clinical endocrinology and metabolism 2004
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
T Claudel, Y Inoue, O Barbier, D Duran-Sandoval, V Kosykh, J Fruchart, JC Fruchart, FJ Gonzalez, B Staels
Gastroenterology 2003
Ragaglitazar: a novel PPARα& PPARγagonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models
R Chakrabarti, RK Vikramadithyan, P Misra, J Hiriyan, S Raichur, RK Damarla, C Gershome, J Suresh, R Rajagopalan
British Journal of Pharmacology 2003
Influence of polymorphism (RFLP-sstI) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism
A Espino-Montoro, M Barrios-Artillo, JM López-Chozas, A Cayuela, P Stiefel, J Villar
Nutrition, Metabolism and Cardiovascular Diseases 2003
Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case–control study
Y Gerber, U Goldbourt, S Segev, D Harats
Preventive Medicine 2003
Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease
SJ Lee, LA Moye, H Campos, GH Williams, FM Sacks
Atherosclerosis 2003
Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice
T Takahashi, T Hirano, K Okada, M Adachi
Metabolism 2003
Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus
SJ Lee, FM Sacks
The American Journal of Cardiology 2003
Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients
JD Morrisett, G Abdel-Fattah, BD Kahan
Transplantation Proceedings 2003
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
O Olivieri, A Bassi, C Stranieri, E Trabetti, N Martinelli, F Pizzolo, D Girelli, S Friso, PF Pignatti, R Corrocher
Journal of lipid research 2003
Effect of apoC-III gene polymorphisms on the lipoprotein-lipid profile of viscerally obese men
C Couillard, MC Vohl, JC Engert, I Lemieux, A Houde, N Alméras, D Prud'homme, A Nadeau, JP Després, J Bergeron
Journal of lipid research 2003
Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions
M Yamamoto, S Morita, M Kumon, M Kawabe, K Nishitsuji, H Saito, A Vertut-Doı̈, M Nakano, T Handa
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2003
The apolipoprotein CIII T2854G variants are associated with postprandial triacylglycerol concentrations in normolipidemic Korean men
SK Woo, HS Kang
Journal of Human Genetics 2003
Atlas of Atherosclerosis
PW Wilson
2003
Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians
S Chhabra, R Narang, LR Krishnan, S Vasisht, DP Agarwal, LM Srivastava, SC Manchanda, N Das
BMC genetics 2002
Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids
J Graaf, MJ Veerkamp, AF Stalenhoef
Journal of the Royal Society of Medicine 2002
Lipoprotein lipase: genetics, lipid uptake, and regulation
M Merkel
The Journal of Lipid Research 2002
Orphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter
H Coste, JC Rodrı́guez
The Journal of biological chemistry 2002
Metabolic origins and clinical significance of LDL heterogeneity
KK Berneis, RM Krauss
Journal of lipid research 2002
ApoC-III gene polymorphisms and risk of coronary artery disease
O Olivieri, C Stranieri, A Bassi, B Zaia, D Girelli, F Pizzolo, E Trabetti, S Cheng, MA Grow, PF Pignatti, R Corrocher
Journal of lipid research 2002
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
HN Ginsberg
Circulation 2002
Markers of Triglyceride-rich Lipoprotein Remnant Metabolism in Visceral Obesity
DC Chan, GF Watts, PH Barrett, JC Mamo, TG Redgrave
Clinical chemistry 2002
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
JD Morrisett, G Abdel-Fattah, R Hoogeveen, E Mitchell, CM Ballantyne, HJ Pownall, AR Opekun, JS Jaffe, S Oppermann, BD Kahan
Journal of lipid research 2002
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
NS Shachter
Current Opinion in Lipidology 2001
Differential metabolism of human VLDL according to content of ApoE and ApoC-III
K Tomiyasu, BW Walsh, K Ikewaki, H Judge, FM Sacks
Arteriosclerosis, thrombosis, and vascular biology 2001
Genetic influences on lipid metabolism trait variability within the Stanislas Cohort
C Pallaud, R Gueguen, C Sass, M Grow, S Cheng, G Siest, S Visvikis
Journal of lipid research 2001
Dietary fat saturation distinctly affects apolipoprotein gene expression and high density lipoprotein size distribution in two strains of Golden Syrian hamsters
D Smith, YS Ahn, J Pedro-Botet, J Osada, P Mata, EJ Schaefer, JM Ordovas
Nutrition Research 2001
Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E
T Hirano, T Takahashi, S Saito, H Tajima, T Ebara, M Adachi
American journal of physiology. Endocrinology and metabolism 2001
Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia
H Campos, D Perlov, C Khoo, FM Sacks
Journal of lipid research 2001
Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice
MC Jong, PC Rensen, VE Dahlmans, H van der Boom, TJ van Berkel, LM Havekes
Journal of lipid research 2001
Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment
N Attia, V Durlach, M Cambilleau, D Roche, A Girard-Globa
Atherosclerosis 2000
Alteration in Expression Profiles of a Series of Diabetes-Related Genes in db/db Mice Following Treatment With Thiazolidinediones
A Suzuki, T Yasuno, H Kojo, J Hirosumi, S Mutoh, Y Notsu
The Japanese Journal of Pharmacology 2000
Transport des lipidesFonction des apolipoprotéines
B Perret, R Milne, X Collet
Annales de l'Institut Pasteur/Actualités 2000
Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin
NA Le, W Innis-Whitehouse, X Li, R Bakker-Arkema, D Black, WV Brown
Metabolism 2000
Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose
P Duriez, B Staels, JC Fruchart
Annales de l'Institut Pasteur/Actualit�s 2000
Lipoprotein Metabolism and Atherogenesis
T Kita, M Yokode
2000
Characterization of Recombinant Wild Type and Site-Directed Mutations of Apolipoprotein C-III: Lipid Binding, Displacement of ApoE, and Inhibition of Lipoprotein Lipase
H Liu, PJ Talmud, L Lins, R Brasseur, G Olivecrona, F Peelman, J Vandekerckhove, M Rosseneu, C Labeur
Biochemistry 2000
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions
CJ Packard, T Demant, JP Stewart, D Bedford, MJ Caslake, G Schwertfeger, A Bedynek, J Shepherd, D Seidel
Journal of lipid research 2000
Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr
H Liu, C Labeur, CF Xu, R Ferrell, L Lins, R Brasseur, M Rosseneu, KM Weiss, SE Humphries, PJ Talmud
Journal of lipid research 2000
Apolipoprotein C-III can specifically bind to hepatic plasma membranes
D Z Fang, B W Liu
Molecular and Cellular Biochemistry 2000
Apolipoprotein E polymorphism in men and women from a Spanish population: allele frequencies and influence on plasma lipids and apolipoproteins
D Gómez-Coronado, JJ Álvarez, A Entrala, JM Olmos, E Herrera, MÁ Lasunción
Atherosclerosis 1999
Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
JC Fruchart, P Duriez, B Staels
Current Opinion in Lipidology 1999
Fibrates, dyslipoproteinaemia and cardiovascular disease
GF Watts, SB Dimmitt
Current Opinion in Lipidology 1999
Interrelationships between postprandial lipoprotein B:CIII particle changes and high-density lipoprotein subpopulation profiles in mixed hyperlipoproteinemia
Y Saïdi, D Sich, A Camproux, M Egloff, MC Federspiel, V Gautier, A Raisonnier, G Turpin, I Beucler
Metabolism 1999
Hypertriglyceridemia, insulin resistance, and the metabolic syndrome
SM Grundy
The American Journal of Cardiology 1999
Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
HB Brewer
The American Journal of Cardiology 1999
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase
K Schoonjans, J Peinado-Onsurbe, JC Fruchart, A Tailleux, C Fiévet, J Auwerx
FEBS Letters 1999
Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size
ED Breyer, NA Le, X Li, D Martinson, WV Brown
Journal of lipid research 1999
Mitogen-activated Protein Kinase Regulates Transcription of the ApoCIII Gene: INVOLVEMENT OF THE ORPHAN NUCLEAR RECEPTOR HNF4
S Reddy, W Yang, DG Taylor, X Shen, D Oxender, G Kust, T Leff
The Journal of biological chemistry 1999
Detection, Quantification, and Characterization of Potentially Atherogenic Triglyceride-Rich Remnant Lipoproteins
JS Cohn, C Marcoux, J Davignon
Arteriosclerosis, thrombosis, and vascular biology 1999
Contemporary Concepts in Cardiology
R Gorlin, G Dangas, PK Toutouzas, MM Konstadoulakis
1999
Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content
C Khoo, H Campos, H Judge, FM Sacks
Journal of lipid research 1999
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids
N Vu-Dac, P Gervois, IP Torra, JC Fruchart, V Kosykh, T Kooistra, HM Princen, J Dallongeville, B Staels
Journal of Clinical Investigation 1998
Defects of lipoprotein metabolism in familial combined hyperlipidaemia
J Graaf, AF Stalenhoef
Current Opinion in Lipidology 1998
LIPOPROTEIN PHYSIOLOGY
HN Ginsberg
Endocrinology & Metabolism Clinics of North America 1998
A peptide from hog plasma that inhibits human cholesteryl ester transfer protein
K Cho
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1998
PPAR$gamma; activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
G Martin, K Schoonjans, B Staels, J Auwerx
Atherosclerosis 1998
ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice
E Voyiaziakis, IJ Goldberg, AS Plump, EM Rubin, JL Breslow, LS Huang
Journal of lipid research 1998
Transient triglyceridemia in healthy normolipidemic men increases cellular processing of large very low density lipoproteins by fibroblasts in vitro
J Björkegren, F Karpe, S Vitols, P Tornvall, A Hamsten
Journal of lipid research 1998
Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma
J Björkegren, F Karpe, RW Milne, A Hamsten
Journal of lipid research 1998
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
T Ebara, R Ramakrishnan, G Steiner, NS Shachter
Journal of Clinical Investigation 1997
Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: Interaction between genotype, gender, and smoking status
RE Peacock, A Temple, V Gudnason, M Rosseneu, SE Humphries
Genetic Epidemiology 1997
The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
B Staels, K Schoonjans, JC Fruchart, J Auwerx
Biochimie 1997
Inhibitory Effects of Specific Apolipoprotein C-III Isoforms on the Binding of Triglyceride-rich Lipoproteins to the Lipolysis-stimulated Receptor
CJ Mann, AA Troussard, FT Yen, N Hannouche, J Najib, JC Fruchart, V Lotteau, P André, BE Bihain
The Journal of biological chemistry 1997
Lipoprotein Heterogeneity and Apolipoprotein B Metabolism
CJ Packard, J Shepherd
Arteriosclerosis, thrombosis, and vascular biology 1997
Alterations of VLDL composition during alimentary lipemia
J Björkegren, A Hamsten, RW Milne, F Karpe
Journal of lipid research 1997
A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia
J Ribalta, AE Ville, JC Vallvé, S Humphries, PR Turner, L Masana
Journal of lipid research 1997
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl
NS Shachter, T Ebara, R Ramakrishnan, G Steiner, JL Breslow, HN Ginsberg, JD Smith
Journal of Clinical Investigation 1996
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR
J Auwerx, K Schoonjans, JC Fruchart, B Staels
Atherosclerosis 1996
In vitro lipolysis of human VLDL: Effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia
HH van Barlingen, LA Kock, FH de Man, DW Erkelens, TW de Bruin
Atherosclerosis 1996
Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes
B Igau, S Lestavel, V Clavey, C Slomianny, P Drouin, R Bresson, JC Fruchart, P Duriez, C Fiévet
Atherosclerosis 1996
Hypolipidemic Effect of Peroxisome Proliferators
R Hertz, J Bishara-Shieban, J Bar-Tana
Annals of the New York Academy of Sciences 1996
Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis
IJ Goldberg
Journal of lipid research 1996
The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
K Schoonjans, B Staels, J Auwerx
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1996
Regulation of Triglyceride Metabolism by PPARs : Fibrates and Thiazolidinediones have Distinct Effects
J Auwerx, K Schoonjans, JC Fruchart, B Staels
Journal of Atherosclerosis and Thrombosis 1996
Drugs Affecting Lipid Metabolism
AM Gotto, R Paoletti, LC Smith, AL Catapano, AS Jackson
1996
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
K Schoonjans, B Staels, J Auwerx
Journal of lipid research 1996
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
B Staels, N Vu-Dac, VA Kosykh, R Saladin, JC Fruchart, J Dallongeville, J Auwerx
Journal of Clinical Investigation 1995
Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
WW Li, MM Dammerman, JD Smith, S Metzger, JL Breslow, T Leff
Journal of Clinical Investigation 1995
Lipids and atherosclerosis
MJ Halpern
Molecular Aspects of Medicine 1995
Characterization of Apolipoproteins B-100, AI and C from Plasma Lipoprotein in the Goose, Anser anser. Evidence for a Genetic Polymorphism in ApoC-like Apolipoproteins
D Hermier, N Sellier, D Rousselot-Pailley, P Forgez
European Journal of Biochemistry 1995
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.: SUPPRESSION OF APOLIPOPROTEIN C-III
R Hertz, J Bishara-Shieban, J Bar-Tana
The Journal of biological chemistry 1995
Elevated Concentrations of Plasma Lipids and Apolipoproteins B, C-III, and E Are Associated With the Progression of Coronary Artery Disease in Familial Hypercholesterolemic Swine
J Hasler-Rapacz, MF Prescott, JV Linden-Reed, JM Rapacz, Z Hu, J Rapacz
Arteriosclerosis, thrombosis, and vascular biology 1995
Modulation of Lipoprotein B Binding to the LDL Receptor by Exogenous Lipids and Apolipoproteins CI, CII, CIII, and E
V Clavey, S Lestavel-Delattre, C Copin, JM Bard, JC Fruchart
Arteriosclerosis, thrombosis, and vascular biology 1995
Association between genetic variation at the APO AI-CIII-AIV gene cluster and familial combined hyperlipidaemia
CF Xu, P Talmud, H Schuster, R Houlston, G Miller, S Humphries
Clinical Genetics 1994
Blood pressure, coronary artery disease, and glycaemic control in type 2 diabetes mellitus: relation to apolipoprotein-CIII gene polymorphism
S Tas, NA Abdella
The Lancet 1994
The effect of beta,beta'-tetramethylhexadecanedioic acid (MEDICA 16) on plasma very-low-density lipoprotein metabolism in rats: role of apolipoprotein C-III
B Frenkel, J Bishara-Shieban, J Bar-Tana
Biochemical Journal 1994
Lipids and apolipoproteins in growth hormone-deficient children during treatment
GB Schaefer, NG Greger, JD Fesmire, PR Blackett, DP Wilson, JP Frindik
Metabolism 1994
Lipoprotein metabolism and its relationship to atherosclerosis
HN Ginsberg
Medical Clinics of North America 1994
Associations of allelic differences at the A-I/C-III/A-IV gene cluster with carotid artery intima-media thickness and plasma lipid transport in hypercholesterolemic-hypertriglyceridemic humans
W Patsch, AR Sharrett, IY Chen, YC Lin-Lee, SA Brown, AM Gotto, E Boerwinkle
Arteriosclerosis Thrombosis and Vascular Biology 1994
Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E
HV de Silva, SJ Lauer, J Wang, WS Simonet, KH Weisgraber, RW Mahley, JM Taylor
The Journal of biological chemistry 1994
Identification of functional domains in the plasma apolipoproteins by analysis of inter-species sequence variability
RB Weinberg
Journal of lipid research 1994
Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III(Asp45–>Asn), in a Turkish patient
S Lüttmann, A von Eckardstein, W Wei, H Funke, E Köhler, RW Mahley, G Assmann
Journal of lipid research 1994
Kinetics of lipolysis of very low density lipoproteins by lipoprotein lipase. Importance of particle number and noncompetitive inhibition by particles with low triglyceride content
PW Connelly, GF Maguire, C Vezina, RA Hegele, A Kuksis
The Journal of biological chemistry 1994
Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
N Maeda, H Li, D Lee, P Oliver, SH Quarfordt, J Osada
The Journal of biological chemistry 1994
Lipoprotein Metabolism: An Overview
J Shepherd
Drugs 1994
Metabolism of triglyceride-rich lipoproteins during alimentary lipemia
F Karpe, G Steiner, T Olivecrona, LA Carlson, A Hamsten
Journal of Clinical Investigation 1993
Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis
A Tybjærg-Hansen, BG Nordestgaard, LU Gerdes, O Færgeman, SE Humphries
Atherosclerosis 1993
Nucleotide sequences of the Macaca fascicularis apolipoprotein C-III and A-IV genes
J Osada, M Pocoví, RJ Nicolosi, EJ Schaefer, JM Ordovás
Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1993
Quantification of Human Plasma Apolipoproteins C-I, C-II, and C-III by Radioimmunoassays
ND Bren, A Rastogi, BA Kottke
Mayo Clinic Proceedings 1993
Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice
C Glass, RC Pittman, DB Weinstein, D Steinberg
Arteriosclerosis Thrombosis and Vascular Biology 1993
Modulation of the expression of human LDL-Apo B-100 epitopes by lipids and apolipoproteins
P Harduin, A Tailleux, JC Fruchart, C Fievet
Arteriosclerosis Thrombosis and Vascular Biology 1993
HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age
F Karpe, JM Bard, G Steiner, LA Carlson, JC Fruchart, A Hamsten
Arteriosclerosis Thrombosis and Vascular Biology 1993
Impaired chylomicron remnant clearance in familial combined hyperlipidemia
MC Cabezas, TW de Bruin, H Jansen, LA Kock, W Kortlandt, DW Erkelens
Arteriosclerosis Thrombosis and Vascular Biology 1993
Role of thyroid hormone in the expression of apolipoprotein A-IV and C-III genes in rat liver
YC Lin-Lee, W Strobl, S Soyal, M Radosavljevic, M Song, AM Gotto, W Patsch
Journal of lipid research 1993
Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins
L Tornoci, CA Scheraldi, X Li, H Ide, IJ Goldberg, NA Le
Journal of lipid research 1993
Effect of sucrose diet on expression of apolipoprotein genes A-I, C-III and A-IV in rat liver
M Radosavljevic, Y Lin-Lee, SM Soyal, W Strobl, C Seelos, AM Gotto, W Patsch
Atherosclerosis 1992
Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells
M Mietus-Snyder, FM Sladek, GS Ginsburg, CF Kuo, JA Ladias, JE Darnell, SK Karathanasis
Molecular and cellular biology 1992
Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia
A Eckardstein, H Holz, M Sandkamp, W Weng, H Funke, G Assmann
Journal of Clinical Investigation 1991
Clinical chemistry
DJ Anderson, FV Lente, FS Apple, SC Kazmierczak, JA Lott, MK Gupta, N McBride, WE Katzin, RE Scott, al.
Analytical Chemistry 1991
Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells
G Agnani, JM Bard, L Candelier, S Delattre, JC Fruchart, V Clavey
Arteriosclerosis Thrombosis and Vascular Biology 1991
Familial combined hyperlipidaemia linked to the apolipoprotein AI–CIII–AIV gene cluster on chromosome 11q23q–q24
AP Wojciechowski, M Farrall, P Cullen, TM Wilson, JD Bayliss, B Farren, BA Griffn, MJ Caslake, CJ Packard, J Shepherd, R Thakker, J Scott
Nature 1991
Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E
L Chivot, F Mainard, E Bigot, JM Bard, JL Auget, Y Madec, JC Fruchart
Atherosclerosis 1990
The 3′-Flanking Region Shared by the Human Apolipoprotein AI and CIII Gene Regulates Gene Expression in Cooperation with 5′-Flanking Elements
A HAASE, W STOFFEL
Biological Chemistry Hoppe-Seyler 1990
Lipid and apoprotein modifications in body builders during and after self-administration of anabolic steroids
G Baldo-Enzi, F Giada, G Zuliani, L Baroni, E Vitale, G Enzi, P Magnanini, R Fellin
Metabolism 1990
Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B
R Ramakrishnan, Y Arad, S Wong, HN Ginsberg
Journal of lipid research 1990
9 Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease
A Hamsten
Baillière's Clinical Endocrinology and Metabolism 1990
Lipoprotein Physiology and Its Relationship to Atherogenesis
HN Ginsberg
Endocrinology and metabolism clinics of North America 1990
Role of triglyceride-rich lipoproteins in progression of atherosclerosis
RJ Havel
Circulation 1990
Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors
DH Blankenhorn, P Alaupovic, E Wickham, HP Chin, SP Azen
Circulation 1990
Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics
CL Malmendier, P Alaupovic, HB Brewer
1990
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Y Ito, N Azrolan, A O'Connell, A Walsh, JL Breslow
Science 1990
Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis
D Robert, R Jeanmonod, H Favre, JC Fruchart, E Sturzenegger, W Riesen
Metabolism 1989
Lipoprotein lipase in rat heart—II. influence of apolipoproteins and nutritional factors on tri- di- and monoacylglycerol lipase activities in post-heparin effluents
A Verine, M Benkirane, JM Meignen, J Boyer
Comparative Biochemistry and Physiology Part B: Comparative Biochemistry 1989
Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis
GS Tint, H Ginsberg, G Salen, NA Le, S Shefer
Journal of lipid research 1989
Very low density lipoprotein apolipoprotein B metabolism in humans
T Demant, J Shepherd, CJ Packard
Klinische Wochenschrift 1988
Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins
NA Le, JC Gibson, HN Ginsberg
Journal of lipid research 1988
The hypochylomicronemic effect of beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) is mediated by a decrease in apolipoprotein C-III
B Frenkel, N Mayorek, R Hertz, J Bar-Tana
The Journal of biological chemistry 1988
Hypolipidemic effect of beta, beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats
J Bar-Tana, G Rose-Kahn, B Frenkel, Z Shafer, M Fainaru
Journal of lipid research 1988
Activation of lipoprotein lipase by apolipoprotein C-II is modulated by the COOH terminal region of apolipoprotein C-III
AL Catapano
Chemistry and Physics of Lipids 1987
1 Lipid transport through the plasma: the metabolic basis of hyperlipidaemia
J Shepherd, CJ Packard
Baillière's Clinical Endocrinology and Metabolism 1987
7 Enzymes involved in triglyceride hydrolysis
MR Taskinen, T Kuusi
Baillière's Clinical Endocrinology and Metabolism 1987
Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes
CS Wang, P Alaupovic, RE Gregg, HB Brewer
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1987
Structure and expression of dog apolipoprotein C-II and C-III mRNAs. Implications for the evolution and functional constraints of apolipoprotein structure
S Datta, WH Li, I Ghosh, CC Luo, L Chan
The Journal of biological chemistry 1987

← Previous 1 2 3 … 14 15 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
73 readers on Mendeley
See more details